Altimmune, Inc. (ALT)

NASDAQ: ALT · Real-Time Price · USD
5.42
0.00 (0.00%)
Jun 4, 2025, 2:12 PM - Market open
0.00%
Market Cap 439.60M
Revenue (ttm) 20,000
Net Income (ttm) -90.24M
Shares Out 81.11M
EPS (ttm) -1.25
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,679,968
Open 5.39
Previous Close 5.42
Day's Range 5.34 - 5.57
52-Week Range 3.55 - 11.16
Beta 0.57
Analysts Strong Buy
Price Target 21.00 (+287.45%)
Earnings Date May 13, 2025

About ALT

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1997
Employees 59
Stock Exchange NASDAQ
Ticker Symbol ALT
Full Company Profile

Financial Performance

In 2024, Altimmune's revenue was $20,000, a decrease of -95.31% compared to the previous year's $426,000. Losses were -$95.06 million, 7.48% more than in 2023.

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for ALT stock is "Strong Buy." The 12-month stock price forecast is $21.0, which is an increase of 287.45% from the latest price.

Price Target
$21.0
(287.45% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Altimmune Vs. Viking Therapeutics: Evaluating Pipeline Maturity, And Takeover Potential

I rate Altimmune a 'Strong Buy' and Viking Therapeutics a 'Buy' for high-risk, long-term investors. ALT's Pemvidutide stands out for its lean mass protection, visceral fat reduction, and potential in ...

Other symbols: VKTX
2 days ago - Seeking Alpha

Altimmune: Upcoming MASH Data Could Be High Impact For Business Development Activity

ALT is approach a readout from IMPACT, a phase 2b study of pemvidutide in MASH. MDGL's results with its launch of MASH drug Rezdiffra demonstrate the multi-billion-dollar potential of a MASH drug, alt...

6 days ago - Seeking Alpha

Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD)

GAITHERSBURG, Md., May 19, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometab...

16 days ago - GlobeNewsWire

Altimmune to Participate at Two Upcoming Investor Conferences

GAITHERSBURG, Md., May 14, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometab...

21 days ago - GlobeNewsWire

Altimmune, Inc. (ALT) Q1 2025 Earnings Call Transcript

Altimmune, Inc. (NASDAQ:ALT) Q1 2025 Earnings Conference Call May 13, 2025 8:30 AM ET Company Participants Lee Roth - President, Burns McClellan, Investor Relations Advisors Vipin Garg - Chief Execut...

21 days ago - Seeking Alpha

Altimmune Announces First Quarter 2025 Financial Results and Business Update

Top-line data from IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) expected in Q2 2025 Phase 2 trials in Alcohol Use Disorder (AUD) and Alcohol Liver Di...

22 days ago - GlobeNewsWire

Altimmune Secures Up to $100 Million in Credit Facility from Hercules Capital

GAITHERSBURG, Md., May 13, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometab...

Other symbols: HTGC
22 days ago - GlobeNewsWire

Altimmune Presents New Analyses Predicting High Rates of MASH Resolution on Biopsy following Pemvidutide Treatment at the EASL International Liver Congress™

MASH Resolution Index (MASHResInd) model highly predictive of MASH resolution MASH Resolution Index (MASHResInd) model highly predictive of MASH resolution

27 days ago - GlobeNewsWire

Altimmune to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025

GAITHERSBURG, Md., May 06, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2025 financial...

4 weeks ago - GlobeNewsWire

Altimmune to Present at Upcoming EASL International Liver Congress™ 2025

GAITHERSBURG, Md., May 01, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing next-generation peptide-based therapeutics for liver and c...

4 weeks ago - GlobeNewsWire

Altimmune to Participate in the Citizens Life Sciences Conference

GAITHERSBURG, Md., April 30, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that members of the Company's management team will...

5 weeks ago - GlobeNewsWire

Altimmune: Pemvidutide Differentiation Advancement In MASH Space Continues To Shine

Altimmune, Inc.'s top-line data from the phase 2b IMPACT study using pemvidutide for the treatment of patients with MASH expected in Q2 of 2025. The global non-alcoholic steatohepatitis [NASH] market ...

2 months ago - Seeking Alpha

Altimmune to test obesity drug for alcohol use disorder and related health conditions

Altimmune said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat alcohol use disorder and alcohol-associated liver disease.

2 months ago - Reuters

Altimmune to Host Virtual R&D Day on March 13, 2025

Program to Feature Presentations from Renowned KOLs in Obesity, MASH and Two Additional Indications for Pemvidutide following recent IND Clearances by FDA Program to Feature Presentations from Renowne...

3 months ago - GlobeNewsWire

Altimmune to Participate in the Leerink Global Healthcare Conference

GAITHERSBURG, Md., March 03, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that members of the Company's management team will...

3 months ago - GlobeNewsWire

Altimmune Q4 Earnings Review: The Big News Is The MASH With Obesity Data Readout Due Q2

Altimmune's pemvidutide shows promise in treating MASH with obesity, potentially positioning it as a first-in-class drug targeting both liver health and weight loss. Despite past volatility, ALT stock...

3 months ago - Seeking Alpha

Altimmune, Inc. (ALT) Q4 2024 Earnings Call Transcript

Altimmune, Inc. (NASDAQ:ALT) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Lee Roth - President, Burns McClellan, Investor Relations Advisors Vipin Garg - Chief E...

3 months ago - Seeking Alpha

Altimmune Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Top-line data from Phase 2b IMPACT trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) to be reported in Q2 2025 Investigational New Drug (IND) applications in two addition...

3 months ago - GlobeNewsWire

Seasoned Biopharmaceutical Industry Executives Teri Lawver and Jerry Durso Appointed to Altimmune Board of Directors

Ms. Lawver, former Chief Commercial Officer of Dexcom and Global Vice President at Johnson & Johnson responsible for billion-dollar Immunology and Cardiovascular & Metabolism Portfolios over her 20-ye...

3 months ago - GlobeNewsWire

Altimmune to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on February 27, 2025

GAITHERSBURG, Md., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 202...

3 months ago - GlobeNewsWire

Altimmune's Catalytic Moment In 2025: Pemvidutide's Phase 2b Trial In MASH

Altimmune is a single-molecule company currently trading at a $0.5 billion market cap with a favorable risk-reward profile. The company's existence depends almost entirely on the outcome of the Phase ...

3 months ago - Seeking Alpha

Final Trade: WST, BTC, GLD, ALT

The final trades of the day with the Fast Money traders.

Other symbols: GLDBTCWST
3 months ago - CNBC Television

Altimmune to Participate in the Guggenheim SMID Cap Biotech Conference

GAITHERSBURG, Md., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will parti...

4 months ago - GlobeNewsWire

Altimmune Could Find A Partner For Its Phase 3 Exercise

ALT's end-of-phase 2 meeting with the FDA provided a clear clinical plan for pemvidutide, but the phase 3 program will require 5,000 patients. ALT's $139M in cash is enough to stay afloat for a while ...

5 months ago - Seeking Alpha

Altimmune Added to Nasdaq Biotechnology Index

GAITHERSBURG, Md., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will be added to the Nasdaq Biotechnology Index ...

5 months ago - GlobeNewsWire